Combination therapy by transarterial injection of miriplatin-iodized oil suspension with radiofrequency ablation (RFA) versus microwave ablation (MWA) for small hepatocellular carcinoma: a comparison of therapeutic efficacy.
Aged
Aged, 80 and over
Carcinoma, Hepatocellular
/ therapy
Catheter Ablation
/ methods
Contrast Media
/ administration & dosage
Female
Humans
Iodized Oil
/ administration & dosage
Liver Neoplasms
/ therapy
Male
Microwaves
/ therapeutic use
Middle Aged
Organoplatinum Compounds
/ administration & dosage
Retrospective Studies
Treatment Outcome
Ablative margin
Hepatocellular carcinoma
Microwave ablation (MWA)
Miriplatin
Radiofrequency ablation (RFA)
Journal
Japanese journal of radiology
ISSN: 1867-108X
Titre abrégé: Jpn J Radiol
Pays: Japan
ID NLM: 101490689
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
06
07
2020
accepted:
22
10
2020
pubmed:
6
11
2020
medline:
24
6
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
To compare the technical efficacy and complications of the transarterial injection of a miriplatin-iodized oil suspension combined with radiofrequency ablation (RFA) or microwave ablation (MWA) in the treatment of small hepatocellular carcinomas (HCCs). This retrospective study included 123 HCCs in 101 patients treated with the transarterial injection of a miriplatin-iodized oil suspension and RFA (MPT-RFA) (maximum diameter: 1.5 [Formula: see text] 0.5 cm, range: 0.6-3.0 cm) and 68 HCCs in 49 patients treated with the transarterial injection of a miriplatin-iodized oil suspension and MWA (MPT-MWA) (maximum diameter: 1.6 [Formula: see text] 0.7 cm, range: 0.5-3.0 cm). Technical success was defined as the achievement of an ablative margin of at least 5 mm for each tumor. Technical success, complications, and local tumor progression were compared between the two groups. The initial technical success rate was significantly higher with MPT-MWA (94.1%) than with MPT-RFA (76.4%; P = 0.003). The number of treatment sessions per nodule was significantly lower with MPT-MWA (1.1) than with MPT-RFA (1.3) (P = 0.004). The major complication rates were similar with MPT-RFA (5.8%) and MPT-MWA (2.7%) (P = 0.391). The one-year local tumor progression rate was similar between MPT-RFA (0%) and MPT-MWA (0%) (P = 0.73). MPT-MWA may have improved therapeutic efficiency in the treatment of small HCCs.
Identifiants
pubmed: 33150469
doi: 10.1007/s11604-020-01064-7
pii: 10.1007/s11604-020-01064-7
doi:
Substances chimiques
Contrast Media
0
Organoplatinum Compounds
0
miriplatin
780F0P8N4I
Iodized Oil
8001-40-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
376-386Références
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
doi: 10.1056/NEJMra1713263
Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81(3):e189–93.
doi: 10.1016/j.ejrad.2011.01.122
Tamai T, Oshige A, Tabu K, Tabu E, Ijyuin S, Sakae H, et al. Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma. Oncol Lett. 2017;14(3):3199–206.
doi: 10.3892/ol.2017.6476
Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.
doi: 10.1159/000111714
Xu Z, Xie H, Zhou L, Chen X, Zheng S. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma. Anal Cell Pathol (Amst). 2019;2019:8619096.
Yamakado K, Takaki H, Nakatsuka A, Yamaknaka T, Fujimori M, Hasegawa T, et al. Radiofrequency ablation for hepatocellular carcinoma. Gastrointest Interv. 2014;3(1):35–9.
doi: 10.1016/j.gii.2014.04.002
Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, et al. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol. 2013;24(5):655–66.
doi: 10.1016/j.jvir.2012.12.009
Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, et al. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol. 2010;21(11):1716–24.
doi: 10.1016/j.jvir.2010.06.020
Kim W, Cho SK, Shin SW, Hyun D, Lee MW, Rhim H. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol (NY). 2019;44(6):2283–92.
doi: 10.1007/s00261-019-01952-1
Nakajima K, Yamanaka T, Nakatsuka A, Haruyuki T, Fujimori M, Sugino Y, et al. Clinical utility of radiofrequency ablation following transarterial injection of miriplatin-iodized oil suspension in small hepatocellular carcinoma. Jpn J Radiol. 2016;34(9):640–6.
doi: 10.1007/s11604-016-0567-x
Hasegawa T, Takaki H, Yamanaka T, Fujimori M, Nakatsuka A, Uraki J, et al. Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity. Jpn J Radiol. 2013;31(6):424–7.
doi: 10.1007/s11604-013-0201-0
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, et al. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013;43(9):942–9.
doi: 10.1111/hepr.12041
Hasegawa T, Takaki H, Miyagi H, Nakatsuka A, Uraki J, Yamanaka T, et al. Hyaluronic acid gel injection to prevent thermal injury of adjacent gastrointestinal tract during percutaneous liver radiofrequency ablation. Cardiovasc Intervent Radiol. 2013;36(4):1144–6.
doi: 10.1007/s00270-013-0546-x
Yamakado K, Nakatsuka A, Takaki H, Sakurai H, Isaji S, Yamamoto N, et al. Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofrequency ablation. Am J Roentgenol. 2010;194(2):530–5.
doi: 10.2214/AJR.09.2917
Choe J, Kim KW, Kim YI, Chung JW, Huh J, Park J, et al. Feasibility of a low-power radiofrequency ablation protocol to delay steam popping. J Vasc Interv Radiol. 2016;27(2):268–74.
doi: 10.1016/j.jvir.2015.10.009
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691-705 e4.
doi: 10.1016/j.jvir.2014.08.027
Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247(1):260–6.
doi: 10.1148/radiol.2471070818
Alonzo M, Bos A, Bennett S, Ferral H. The emprint ablation system with thermosphere technology: one of the newer next-generation microwave ablation technologies. Semin Interv Radiol. 2015;32(4):335–8.
doi: 10.1055/s-0035-1564811
Ierardi AM, Mangano A, Floridi C, Dionigi G, Biondi A, Duka E, et al. A new system of microwave ablation at 2450 MHz: preliminary experience. Updates Surg. 2015;67(1):39–45.
doi: 10.1007/s13304-015-0288-1
Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(8):1054–63.
doi: 10.4254/wjh.v7.i8.1054
Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms—review article. Rofo. 2017;189(11):1055–66.
doi: 10.1055/s-0043-117410
Miyazaki M, Iguchi T, Takaki H, Yamanaka T, Tamura Y, Tokue H, et al. Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts. Jpn J Radiol. 2016;34(9):647–56.
doi: 10.1007/s11604-016-0569-8
Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115–22.
doi: 10.1111/j.1440-1746.2010.06543.x
Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, et al. Complications after radiofrequency ablation for hepatocellular carcinoma: a multicenter study involving 9,411 Japanese patients. Liver cancer. 2020;9(1):50–62.
doi: 10.1159/000502744
Hermida M, Cassinotto C, Piron L, Assenat E, Pageaux GP, Escal L, et al. Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. Int J Hyperth. 2018;35(1):90–6.
doi: 10.1080/02656736.2018.1477206
Takaki H, Yamakado K, Nakatsuka A, Yamada T, Shiraki K, Takei Y, et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience. Am J Roentgenol. 2013;200(3):658–64.
doi: 10.2214/AJR.12.8691
Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther. 2016;7(4):477–89.
doi: 10.4292/wjgpt.v7.i4.477
Luo W, Zhang Y, He G, Yu M, Zheng M, Liu L, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol. 2017;15(1):126.
doi: 10.1186/s12957-017-1196-2
Tan W, Deng Q, Lin S, Wang Y, Xu G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperth. 2019;36(1):264–72.
Suwa K, Seki T, Tsuda R, Yamashina M, Murata M, Yamaguchi T, et al. Short term treatment results of local ablation with water-cooled microwave antenna for liver cancer: comparison with radiofrequency ablation. Mol Clin Oncol. 2020;12(3):230–6.
pubmed: 32064099
pmcid: 7016568